SPRUCE BIOSCIENCES NOW ENROLLING CAHMELIA CLINICAL TRIAL

This study is designed to evaluate the efficacy of tildacerfont on disease control or reduction of glucocorticoid use in pediatric subjects with classic CAH.​

• Sponsor: Spruce Biosciences
• Study Contact: Clinical Trials phone number: 415-655-4169: [email protected]
• Who should consider participating: Children and teenagers, age 2-17, diagnosed with CAH due to 21-hydroxylase deficiency and/or elevated 17-hydroxyprogesterone requiring ongoing glucocorticoid replacement.
• https://clinicaltrials.gov/study/NCT05128942